Pandemic Preparedness Financing Gap: WHO Reform and Sovereign Fund Readiness

Executive Summary

The global pandemic preparedness financing architecture remains structurally underfunded relative to the benchmarks set after COVID-19, even as new instruments have come online and WHO governance reforms have advanced further than most observers acknowledge. The G20 High-Level Independent Panel's November 2025 report, "Closing the Deal," warned that "the architecture for pandemic preparedness is full of cracks," with high-income countries pulling back foreign aid precisely as the threat frequency of infectious disease outbreaks continues to increase. The WHO Pandemic Agreement, adopted by the World Health Assembly on 20 May 2025, and IHR amendments that entered into force in September 2025 represent the most significant structural reform in a generation, but their enforceability gaps and the unresolved Pathogen Access and Benefit Sharing annex constrain their near-term operational impact. The Pandemic Fund, a World Bank-hosted Financial Intermediary Fund, has mobilised over US$11.5 billion across 128 countries as of February 2026, but the core annual financing shortfall against the established $15 billion per-year benchmark for international public goods remains unmet.

• Risk officers and health security leads: Model a 24-36 month window of structural vulnerability during which the WHO Pandemic Agreement is open for signature but not yet in force, and national surveillance capacities in low- and middle-income countries remain under-resourced relative to IHR 2024 requirements.
• Policy and government stakeholders: The September 2026 UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response is the single highest-leverage decision point in the near term; absence of binding financing commitments from G7 member states at that meeting would confirm the gap will persist into the next decade.
• Corporate operations/supply-chain: Biodefense uncertainty compounds existing supply-chain risk, as the Washington Post reported in August 2026 that the Trump administration is actively rebuilding bioweapons defenses while AI-enabled protein design is accelerating the threat surface faster than current international surveillance frameworks can track.

The WHO Pandemic Agreement and IHR reforms have materially advanced governance, but without sustained sovereign financing at the $15 billion annual benchmark, the instruments create legal architecture without the operational capacity to act on it.

The Governance Architecture: What May 2025 Actually Changed

The adoption of the WHO Pandemic Agreement on 20 May 2025 is the most significant structural reform in global health governance since the IHR were last substantively revised in 2005. WHO member states reached consensus text on 16 April 2025, after a negotiating process the Intergovernmental Negotiating Body began in 2021. The Coalition for Epidemic Preparedness Innovations (CEPI) described the agreement as targeting "pandemic prevention and surveillance capacities, improved routine immunisation and a One Health approach." The IHR 2024 amendments, which entered into force in September 2025, complement the agreement by creating binding national obligations on surveillance and reporting.

Yet the architecture has a load-bearing gap. The Pathogen Access and Benefit Sharing annex, Article 12 of the agreement, was explicitly deferred to a new Intergovernmental Working Group, which is to report to the 79th World Health Assembly. This annex determines how sharing of pathogen sequences and biological samples is coupled to equitable access to the vaccines and therapeutics those sequences enable. A scoping review covering 52 peer-reviewed studies on pandemic governance challenges from 2020-2024, published in open-access NIH literature, found that "inequitable access to medical countermeasures" was among the most persistent and least resolved governance failures of the COVID-19 response. Deferring the PABS annex means the agreement enters its signature phase without the provision that would most directly change the incentive calculus for low- and middle-income countries to share pathogen data rapidly in a future outbreak.

What is not being reported: the ratification timeline for the Pandemic Agreement is structurally uncertain. An agreement that is adopted by the World Health Assembly but not yet ratified by a sufficient number of member states carries no binding force. The public debate treats adoption as the milestone, but the operational milestone is entry into force, and that clock has not yet started.

The WHO Framework for Health Emergency Preparedness, published in March 2026, outlines 12 core capabilities covering foundational domains, including "legal authority, evidence generation and use for policy, and secure and flexible financing," alongside technical domains such as "surveillance and intelligence, laboratory and diagnostic systems" and "countermeasure research and deployment." This framework, building on both the IHR 2024 amendments and the Pandemic Agreement, represents WHO's operational translation of the governance reforms. But frameworks without commensurate financing translate directly into member states with new legal obligations and insufficient means to meet them.

The Financing Gap: Stock, Flow, And The $15 Billion Benchmark

The G20 endorsed a $15 billion annual international financing benchmark for pandemic preparedness and response as a public goods investment target. The WHO and G20 have separately called for an additional $10.5 billion per year specifically to adequately strengthen the global PPR architecture. Both figures derive from analysis prepared for the G20 Joint Finance and Health Task Force. Prior academic research, including modelling published in the Lancet, estimated that between $96 billion and $204 billion would be required globally to advance national health security capacities, with $63-131 billion needed over a three-year period. These figures sit well above current committed flows.

Trajectory, not just level: the Pandemic Fund's portfolio of US$11.5 billion as of February 2026 sounds substantial relative to the per-year benchmarks, but this is a stock of mobilised resources across all time periods and contributing countries, not an annual flow. The grant component, at US$1.4 billion across three funding rounds, represents the actual new money transferred to preparedness-building activities. The remaining $10 billion in "catalysed resources" consists of domestic and co-financing commitments that are contingent on country implementation capacity and sustained political will, both of which are highly variable in lower-income settings.

The G20 HLIP's November 2025 report, "Closing the Deal," called for decisive action by or before September 2026, explicitly warning that "global health financing is eroding just as the threats of pandemic and deliberate biological events are rising." The Independent Panel on Pandemic Preparedness and Response, a separate expert body, published its own analysis in May 2025, supporting the concept of "global public investment whereby all countries contribute based on an ability to pay formula," shifting from the current voluntary contribution model. If adopted, this model would represent a structural change from charity-based to rights-based pandemic financing, closing the dependency on high-income donor political cycles.

The SDG framework's own tracking data from the UN Department of Economic and Social Affairs confirms that "even before the pandemic, the global proportion of the population with out-of-pocket health spending exceeding 10% of their household budget was on the rise," documenting the pre-existing fiscal fragility of health systems in lower-income countries that pandemic preparedness investments must be layered onto.

The Surveillance Capacity Gap: Africa And Ai As The Dual Exposure

WHO's Global Influenza Surveillance and Response System now processes over 12 million samples worldwide annually for influenza characterisation, and by 2025 all countries in the WHO European Region had access to next-generation sequencing for real-time virus mutation tracking, per WHO Europe's May 2026 reporting on the 15-year Pandemic Influenza Preparedness Framework. The number of countries with in-country SARS-CoV-2 genomic sequencing capability increased by 40% between February 2021 and July 2022, according to WHO regional analysis published in peer-reviewed literature. Under the Pandemic Influenza Preparedness Framework, WHO signed eight new agreements with pandemic product manufacturers in 2025 alone, bringing the total to 19 contracts.

These are real gains. But the Brookings Institution's 2021 assessment of African health systems documented that the continent remained "the least-prepared region when it comes to preventing the emergence or release of pathogens," with structural underinvestment compounded by brain drain and limited social protection. The Pandemic Fund's portfolio spans 128 countries, but the per-country grant allocation is insufficient to close multi-decade infrastructure deficits. This constraint on African surveillance capacity translates directly into a global detection risk: pathogens that emerge where surveillance is thinnest generate the longest pre-detection windows, which are the most consequential variable in outbreak containment.

The second surveillance gap is newer and less discussed. The Washington Post's August 2026 reporting confirmed that AI can now design toxic proteins that are "escaping through biosecurity cracks," and that the Trump administration is actively rebuilding biodefense infrastructure in response. WHO's March 2026 framework covers surveillance and intelligence as a core capability, but the Pandemic Fund, the Global Fund, and the PIP Framework were all designed around biological threats with natural origins. No multilateral financing window currently exists for AI-enabled biosurveillance, creating a structural blind spot that the broader geopolitical and health security dimensions of AI risk compound.

What is not being reported: the publicly available evidence on AI-enabled pathogen design is almost entirely filtered through US national security perspectives and Western biosecurity institutions. Surveillance of this threat in settings without dedicated biodefense establishments, including most of sub-Saharan Africa and Central Asia, is effectively absent from the multilateral risk picture.

The table below maps the assumptions underpinning this assessment. Each row names the assumption, the evidence supporting and potentially falsifying it, the consequence of being wrong, and the single most observable data point that would confirm or falsify the assumption.

Counterarguments

1. The Pandemic Fund's catalytic model may be more durable than the grant-count suggests: Critics of the "financing gap" framing, including some World Bank analysts, argue that the $10 billion in co-financing catalysed by $1.4 billion in Pandemic Fund grants represents a leverage ratio that conventional development finance rarely achieves. If domestic budget integration in recipient countries is real rather than cosmetic, the $10 billion figure reflects a genuine shift in how countries prioritise health security spending. The HLIP November 2025 report's concern that "few nations have integrated pandemic preparedness into domestic budgets" is the key falsifying evidence for this counterargument, but the evidence on implementation quality is not yet available in peer-reviewed form.

2. WHO reform may be more substantive than the governance-gap literature reflects: The scoping review finding that "persistent gaps in governance and limited enforceability" characterise pandemic preparedness draws primarily on literature published between 2020 and 2024, predating both the May 2025 Pandemic Agreement adoption and the September 2025 IHR amendments. WHO's Berlin Pandemic Hub, established in September 2021 with EUR 90 million in German federal funding, and the Global Genomic Surveillance Strategy launched in March 2022, represent real institutional capacity additions. An analyst who weighted post-2024 institutional developments more heavily than the pre-reform governance literature would reach a more optimistic conclusion on WHO's trajectory.

3. The donor coalition fracture may be partially offset by non-traditional contributors: The Independent Panel's May 2025 report explicitly supported "a global public investment model" with contributions based on ability to pay, implying new contributors from the Global South, particularly China, India, and Gulf states, could partially replace reductions in US and European contributions. China's engagement with the WHO framework and its capacity to fund regional surveillance infrastructure through bilateral health cooperation agreements is underweighted in Western-centric analyses of the financing landscape. The evidence base for quantifying this potential offset is thin.

Indicators To Watch

The table below identifies the observable signals that would confirm, modify, or falsify the primary assessment. Warning thresholds are the specific conditions that would require this analysis to be revised.

Near-term watch list: (1) September 2026 UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response, the G20 HLIP's explicit target date for binding financing commitments; absence of new sovereign pledges at this meeting would confirm the structural financing gap persists beyond the current governance reform window. (2) Pandemic Fund Round 4 grant allocation announcement, expected Q4 2026 to Q1 2027, which will reveal whether donor concentration has shifted and whether per-country grant sizes in Africa and South Asia have increased. (3) IGWG first substantive session on the PABS annex, expected Q1 2027, where the gap between high-income country preference for voluntary sharing and LMIC preference for mandatory access will either narrow or harden.

Decision Relevance

Scenario A (~55%): Sustained but insufficient financing, with the September 2026 UN HLM producing incremental pledges but no binding sovereign commitments. If you advise on global health security policy or manage health-linked sovereign risk, treat this as the base case and plan for a 5-10 year implementation window before IHR obligations are genuinely met in the majority of low-income member states. If you are a pharmaceutical or diagnostics company with pandemic-related product pipelines, the Pandemic Fund remains the most accessible multilateral grant facility, but competition for Round 4 grants will be significant; engage early and focus on surveillance technology with clear LMIC deployment pathways. If you lack direct exposure to this domain, monitor the IGWG PABS annex process as the leading indicator of whether the agreement acquires operational equity provisions, because without them, pathogen data sharing in a future outbreak will be slower than it was in early COVID-19.

Scenario B (~30%): US foreign aid and Pandemic Fund contribution reductions materially reduce catalytic leverage, triggering a co-financing validation process. If you operate in health security-adjacent sectors, model a scenario where the Pandemic Fund's $10 billion co-financing collapses to a fraction of current projections, reverting the effective preparedness investment in low-income countries to pre-2022 trajectories. The Wellcome Trust's John-Arne Rottingen, co-chair of the HLIP, stated in November 2025 that "the next pandemic will not wait for us to fix what's broken"; this scenario is the operational meaning of that warning. For corporate risk officers: a scenario with 12-18 month earlier outbreak detection failure in Sub-Saharan Africa or South Asia would compound supply-chain disruption risks faster than in COVID-19 because global production networks are now more concentrated in vulnerable geographies than in 2019.

Scenario C (~15%): The PABS annex is resolved at the 79th World Health Assembly, the agreement enters into force rapidly, and a new global public investment model generates sufficient financing to approach the $15 billion annual benchmark. If you advise on multilateral governance frameworks, begin pre-positioning analysis of how a mandatory PABS mechanism would restructure vaccine and diagnostic market access rules, because the implications for intellectual property and manufacturing licensing in a future emergency would be materially different from the COVID-19 experience. If you hold positions in global health security-linked development finance, this scenario is the bull case: a functioning Pandemic Agreement with PABS teeth and adequate financing would validate the entire post-2020 investment in preparedness infrastructure.

Expert Integration

Expert Consensus Assessment

Government, academic, and multilateral institutional literature converges on the finding that the governance architecture has advanced materially since 2021, but the financing gap against established benchmarks persists and has worsened relative to need as high-income countries pull back foreign aid. There is genuine disagreement on the adequacy of the Pandemic Fund's catalytic model.

Expert Disagreement Areas

• Financing adequacy: The Pandemic Fund itself characterises its portfolio as having "moved quickly to fill critical investment gaps" (February 2026 self-assessment), while the G20 HLIP "Closing the Deal" report (November 2025) describes global health financing as "eroding" against rising threats. These are not reconcilable framings, and they reflect genuine methodological disagreement about whether catalysed co-financing counts toward the $15 billion benchmark.
• WHO reform depth: The Wellcome Trust-aligned academic literature (co-chair Rottingen's panel) treats current reforms as necessary but insufficient. WHO's own February 2026 six-year retrospective presents a more optimistic picture, citing the IHR amendments, Pandemic Fund, GISRS expansion, and PIP agreements as a coherent system improvement.
• PABS feasibility: High-income country delegations and LMIC blocs hold substantively different positions on mandatory versus voluntary pathogen sharing that the November 2025 literature does not resolve.

Systematic-Expert Alignment

Alignment: MIXED

This assessment aligns with expert consensus on the financing gap's persistence and the governance reform's structural incompleteness, particularly on PABS. It diverges from WHO's more optimistic framing by weighting the unresolved PABS annex and the AI biosecurity gap as higher-order risks than WHO's public communications currently acknowledge.

• The financing gap figures ($15 billion annual benchmark, $10.5 billion additional need) derive from 2021-era G20 task force analysis. No updated benchmark that accounts for post-COVID-19 inflation, geopolitical fragmentation, or AI-enabled biosecurity threats has been published in a form that peer-reviewed literature has yet validated as of August 2026.
• The Pandemic Fund's $10 billion in "catalysed resources" is a co-financing figure that includes domestic budget commitments from recipient countries. The verification methodology for whether these commitments represent new money or re-labelled existing health spending is not publicly available in audited form; this assessment takes the Fund's own reporting at face value.
• The PABS annex negotiation is the most consequential near-term variable for the Pandemic Agreement's operational impact, but IGWG sessions are conducted in restricted diplomatic settings. Public reporting on negotiating positions is filtered through civil society observers with their own advocacy interests.
• The AI-enabled biosecurity threat dimension is currently documented primarily through US national security sources and Western biosecurity researchers. Independent assessment of the threat from non-Western scientific institutions is largely absent from the evidence base, creating a material selection bias in the threat picture.
• This assessment was produced under data freshness constraints: some source material on Pandemic Fund implementation quality and IGWG negotiating dynamics dates from mid-2025, and the picture may have evolved in ways not captured in publicly available documents as of August 2026.